Background: The growing demand for minimally invasive aesthetic procedures highlights the need for innovative injectable solutions that target skin aging beyond volumization. Hyaluronic acid (HA)-based fillers remain a cornerstone of aesthetic treatments, but traditional formulations often offer limited benefits in improving skin quality parameters such as elasticity. This study evaluated the efficacy and safety of an injectable formulation composed of 2.6% high molecular weight hyaluronic acid (H-HA) and 3.2% sorbitol, designed to improve skin biomechanical properties through subcutaneous administration. Methods: In this single-center, open-label, single-arm clinical trial, 86 participants aged 35 to 70 years received a single injection in the facial region. Clinical outcomes were assessed at baseline (day 0), one month (M1), and four months (M4) post-injection using the Global Aesthetic Improvement Scale (GAIS), instrumental Cutometer^® measurements of skin elasticity and recovery, and patient satisfaction questionnaires. Results: Significant improvements in skin elasticity and recovery were observed at M4 following a single administration. The product was well tolerated, with only mild and transient injection site reactions observed. Conclusions: These exploratory findings support the clinical benefit of combining high-concentration H-HA with sorbitol to enhance skin quality in a safe and minimally invasive manner. These preliminary results position this formulation as a promising option for facial rejuvenation, targeting biomechanical improvement through a single-session injectable protocol.